TY - JOUR
T1 - Prostate tumor-initiating cells
T2 - A new target for telomerase inhibition therapy?
AU - Marian, Calin O.
AU - Shay, Jerry W.
N1 - Funding Information:
Supported by a Department of Defense Prostate Cancer Training Award (Grant No. PC074128 to C.O.M.).
PY - 2009/4
Y1 - 2009/4
N2 - Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These "cancer stem cells" are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses.
AB - Conventional therapies for prostate cancer, especially in its androgen-independent form, may result in the survival of small populations of resistant cells with tumor-initiating potential. These "cancer stem cells" are believed to be responsible for cancer relapse, and therapeutic strategies targeting these cells are of great importance. Telomerase is a ribonucleoprotein enzyme responsible for telomere elongation and is activated in the majority of malignancies, including prostate cancer, but is absent in most normal cells. Putative tumor-initiating cells have significant levels of telomerase, indicating that they are an excellent target for telomerase inhibition therapy. In this review, we present some evidence for the hypothesis that conventional therapies (standard chemotherapy and/or radiation therapy) in combination with telomerase inhibitors may result in effective and more durable responses.
KW - GRN163L
KW - Prostate
KW - Telomerase
KW - Telomere
KW - Tumor-initiating cell
UR - http://www.scopus.com/inward/record.url?scp=64249158272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64249158272&partnerID=8YFLogxK
U2 - 10.1016/j.bbadis.2009.02.012
DO - 10.1016/j.bbadis.2009.02.012
M3 - Review article
C2 - 19264126
AN - SCOPUS:64249158272
SN - 0925-4439
VL - 1792
SP - 289
EP - 296
JO - Biochimica et Biophysica Acta - Molecular Basis of Disease
JF - Biochimica et Biophysica Acta - Molecular Basis of Disease
IS - 4
ER -